Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125

Gelijkaardige items

• Response to Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125
  door: Gale, Edwin A.M.
  Gepubliceerd in: (2013)
• The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
  door: Nyborg, Niels C.B., et al.
  Gepubliceerd in: (2012)
• Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer: Summary of an NIDDK-NCI Workshop
  door: Moses, Alan Charles, et al.
  Gepubliceerd in: (2014)
• Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232
  door: Vora, J
  Gepubliceerd in: (2013)
• Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
  door: Marathe, Chinmay S., et al.
  Gepubliceerd in: (2011)